Innovus Pharmaceuticals Results Show Vesele(R) Achieves 58 Percent Increase in Sexual Desire in Women

Innovus Pharmaceuticals Inc. (OTCMKTS:INNV) announced that its top line results from its Vesele(R) US human survey clinical use trial in women with low female sexual dysfunction showed positives in accompanying endpoints.

In the study, the Company reported that Vesele(R) use resulted in the following:

• 58 percent increase desire;
• 40 percent  increase in lubrication;
• 34.2 percent  increase in the frequency of sexual intercourse;
• 45.9 percent  increase in the ability to be aroused; and
• 41 percent  increase in overall satisfaction.

As quoted in the press release:

Pursuant to these results, the Company believes that the data indicate that Vesele(R) was very well tolerated with no serious adverse events reported. The only minor events reported by the clinical trial patients were dry mouth, which was resolved by their drinking 62oz of water daily and sleep disturbance if taken late afternoon.

Vesele(R) is a proprietary oral formulation of arginine and citrulline with the natural absorption enhancer Bioperine(R). Vesele(R) was formulated to increase blood flow and nitric oxide production.

Dr. Bassam Damaj, president and CEO of Innovus Pharma, commented:

We are thrilled about these results from the Vesele(R) study and the magnitude of the responses achieved by the users. To our knowledge, there are no approved products in the U.S. for HSDD. The closest product, we believe, is in late stage development by Sprout Pharmaceuticals and it is awaiting FDA approval. Hence, we believe the market is open for Vesele(R) to be successful in the U.S. for this indication.

Click here to read the full Innovus Pharmaceuticals Inc. (OTCMKTS:INNV) press release.